ImmunoGen, Inc. Announces Webcasts of Presentations at Upcoming Investor Conferences

WALTHAM, Mass.--(BUSINESS WIRE)--

ImmunoGen, Inc. IMGN, a biotechnology company developing targeted cancer therapeutics using its proprietary antibody-drug conjugate (ADC) technology, today announced that the following presentations by Company management at upcoming investor conferences will be webcast:

• UBS Global Healthcare Conference
  9:00 am ET, May 25, 2016

• Jefferies 2016 Healthcare Conference
  10:00 am ET, June 9, 2016

The webcasts will be accessible live through the "Investors" section of the Company's website, www.immunogen.com; a replay will be available at the same location for approximately a week.

About ImmunoGen, Inc.

ImmunoGen is a clinical-stage biotechnology company that develops targeted anticancer therapeutics using its proprietary ADC technology. The Company's lead product candidate, mirvetuximab soravtansine, has demonstrated encouraging activity and tolerability in early clinical testing for folate receptor α-positive ovarian cancer and is progressing to advanced clinical testing. ImmunoGen's ADC technology is used in Roche's marketed product, Kadcyla^®, and in programs in development by partners Amgen, Bayer, Biotest, CytomX, Lilly, Novartis, Sanofi and Takeda. More information about the Company can be found at www.immunogen.com.

Kadcyla^® is a registered trademark of Genentech, a member of the Roche Group.

View source version on businesswire.com: http://www.businesswire.com/news/home/20160511005165/en/